# US 2022/0044819 A1 · Diagnostic and therapeutic methods for the treatment of breast cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0044819 A1
- Document ID: US20220044819A1
- Status: Published application
- Kind: A1
- Application number: 17/359,186
- Filed: 2021-06-25
- Published: 2022-02-10
- Earliest claimed: 2018-08-17
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Anneleen Daemen; Ciara Metcalfe
- Web page: https://patentgrep.com/patent/US20220044819A1

## CPC

- G16H 50/30: for calculating health indices; for individual health risk assessment
- G01N 33/57515: of the breast
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 80/00: ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein, inter alia, are predictive diagnostic, pharmacodynamic, and therapeutic methods for the treatment of breast cancer. In embodiments, the methods and compositions are based, at least in part, on the discovery that the estradiol (E2)-induced score or estrogen receptor (ER) pathway activity score determined from a sample (e.g., a tissue sample, e.g., a tumor tissue sample, e.g., a FFPE, a FF, an archival, a fresh, or a frozen tumor tissue sample) from an individual can be used in methods of determining whether the individual having breast cancer is likely to respond to a treatment including an endocrine therapy, selecting a therapy for an individual having breast cancer; treating an individual having breast cancer; and monitoring therapeutic efficacy of an endocrine therapy, as well as related kits.

## Claims

### Claim at position 1

1-95. (canceled)

### Claim 96

A method of identifying an individual having a breast cancer who may benefit from a treatment comprising an endocrine therapy, the method comprising determining an estrogen receptor (ER) pathway activity score from a sample from the individual;
wherein the ER pathway activity score is calculated by subtracting an E2-repressed score, determined from the average z-scored expression of at least 4 of the E2-repressed genes selected from the group consisting of BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1, and TP53INP2, from an E2-induced score, determined from the average z-scored expression of 23 of the E2-induced genes selected from the group consisting of AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703; and
wherein an ER pathway activity score from the sample that is at or above a reference ER pathway activity score identifies the individual as one who may benefit from a treatment comprising an endocrine therapy.

### Claim 97 (depends on 96)

The method of claim 96, wherein the ER pathway activity score determined from the sample is at or above the reference ER pathway activity score, and the method further comprises administering to the individual an effective amount of an endocrine therapy.

### Claim 98 (depends on 96)

The method of claim 96, wherein the ER pathway activity score is calculated by subtracting an E2-repressed score, determined from the average z-scored expression of all of the E2-repressed genes set selected from the group consisting of BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1, and TP53INP2, from an E2-induced score, determined from the average z-scored expression of all of the E2-induced genes selected from the group consisting of AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703.

### Claim 99 (depends on 96)

The method of claim 96, wherein the endocrine therapy comprises a selective estrogen receptor degrader, a selective estrogen receptor modulator, a selective estrogen receptor covalent antagonist, a selective human estrogen receptor agonist, an aromatase inhibitor, or a combination of two or more thereof.

### Claim 100 (depends on 96)

The method of claim 96, wherein the endocrine therapy comprises letrozole, anastrozole, exemestane, testolactone, hydroxytamoxifen, clomifene, toremifene, raloxifene, anordrin, bazedoxifene, broparestrol, cyclofenil, lasofoxifene, ormeloxifene, acolbifene, elacestrant, brilanestrant, clomifenoxide, droloxifene, etacstil, ospemifene, G1T48, AZ9496, GDC-0927, LX-039, fulvestrant, or GDC-9545, a pharmaceutically acceptable salt of one of the foregoing, or a combination of two or more of the foregoing.

### Claim 101 (depends on 96)

The method of claim 96, wherein the endocrine therapy comprises a compound having formula:
or a pharmaceutically acceptable salt thereof.

### Claim 102

A method for monitoring the response of an individual having a breast cancer to treatment with an endocrine therapy, the method comprising:
(a) determining a first ER pathway activity score from a sample from the individual at a first time point, wherein the first ER pathway activity score is calculated by subtracting an E2-repressed score, determined from the average z-scored expression of at least 4 of the E2-repressed genes selected from the group consisting of BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1, and TP53INP2, from an E2-induced score, determined from the average z-scored expression of 23 of the E2-induced genes selected from the group consisting of AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703;
(b) following step (a), determining a second ER pathway activity score, wherein the second ER pathway activity score is calculated by subtracting an E2-repressed score, determined from the average z-scored expression of at least 4 of the E2-repressed genes selected from the group consisting of BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1, and TP53INP2, from an E2-induced score, determined from the average z-scored expression of 23 of the E2-induced genes selected from the group consisting of AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703 from a sample from the individual at a second time point following administration of an endocrine therapy; and
(c) comparing the first ER pathway activity score with the second ER pathway activity score, wherein a decrease in the second ER pathway activity score relative to the first ER pathway activity score is predictive of an individual who is likely to respond to treatment with an endocrine therapy.

### Claim 103 (depends on 102)

The method of claim 102, wherein the second ER pathway activity score is decreased relative to the first ER pathway activity score, and the method further comprises administering an additional dose of the endocrine therapy to the individual.

### Claim 104 (depends on 102)

The method of claim 102, wherein each ER pathway activity score is calculated by subtracting an E2-repressed score, determined from the average z-scored expression of all of the E2-repressed genes selected from the group consisting of BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1, and TP53INP2, from an E2-induced score, determined from the average z-scored expression of all of the E2-induced genes selected from the group consisting of AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703.

### Claim 105 (depends on 102)

The method of claim 102, wherein the first ER pathway activity score is:
(a) an ER pathway activity score determined from a sample from the individual obtained prior to administration of a first dose of an endocrine therapy;
(b) an ER pathway activity score determined from a sample from the individual at a previous time point, wherein the previous time point is following administration of a first dose of an endocrine therapy; or
(c) a pre-assigned ER pathway activity score.

### Claim 106 (depends on 102)

The method of claim 102, wherein the endocrine therapy comprises a selective estrogen receptor degrader, a selective estrogen receptor modulator, a selective estrogen receptor covalent antagonist, a selective human estrogen receptor agonist, an aromatase inhibitor, or a combination of two or more thereof.

### Claim 107 (depends on 102)

The method of claim 102, wherein the endocrine therapy comprises letrozole, anastrozole, exemestane, testolactone, hydroxytamoxifen, clomifene, toremifene, raloxifene, anordrin, bazedoxifene, broparestrol, cyclofenil, lasofoxifene, ormeloxifene, acolbifene, elacestrant, brilanestrant, clomifenoxide, droloxifene, etacstil, ospemifene, G1T48, AZ9496, GDC-0927, LX-039, fulvestrant, or GDC −9545, a pharmaceutically acceptable salt of one of the foregoing, or a combination of two or more of the foregoing.

### Claim 108 (depends on 102)

The method of claim 102, wherein the endocrine therapy comprises a compound having formula:
or a pharmaceutically acceptable salt thereof.

### Claim 109

A method of identifying an individual having a breast cancer who may benefit from a treatment comprising an endocrine therapy, the method comprising determining an estradiol (E2)-induced score from a sample from the individual as determined from the average z-scored expression of all of the E2-induced genes selected from the group consisting of AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703, wherein an E2-induced score from the sample that is at or above a reference E2-induced score identifies the individual as one who may benefit from a treatment comprising an endocrine therapy.

### Claim 110 (depends on 109)

The method of claim 109, wherein the E2-induced score determined from the sample is at or above the reference E2-induced score, and the method further comprises administering to the individual an effective amount of an endocrine therapy.

### Claim 111 (depends on 109)

The method of claim 109, wherein the endocrine therapy comprises a selective estrogen receptor degrader, a selective estrogen receptor modulator, a selective estrogen receptor covalent antagonist, a selective human estrogen receptor agonist, an aromatase inhibitor, or a combination of two or more thereof.

### Claim 112 (depends on 109)

The method of claim 109, wherein the endocrine therapy comprises letrozole, anastrozole, exemestane, testolactone, hydroxytamoxifen, clomifene, toremifene, raloxifene, anordrin, bazedoxifene, broparestrol, cyclofenil, lasofoxifene, ormeloxifene, acolbifene, elacestrant, brilanestrant, clomifenoxide, droloxifene, etacstil, ospemifene, G1T48, AZ9496, GDC-0927, LX-039, fulvestrant, or GDC −9545, a pharmaceutically acceptable salt of one of the foregoing, or a combination of two or more of the foregoing.

### Claim 113 (depends on 109)

The method of claim 109, wherein the endocrine therapy comprises a compound having formula:
or a pharmaceutically acceptable salt thereof.

### Claim 114

A method for monitoring the response of an individual having a breast cancer to treatment with an endocrine therapy, the method comprising:
(a) determining a first E2-induced score from a sample from the individual at a first time point wherein the first E2-induced score is determined from the average z-scored expression of all of the E2-induced genes selected from the group consisting of AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703;
(b) following step (a), determining a second E2-induced score from a sample from the individual at a second time point following administration of an endocrine therapy, wherein the second E2-induced score is determined from the average z-scored expression of all of the E2-induced genes selected from the group consisting of AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703; and
(c) comparing the first E2-induced score with the second E2-induced score, wherein a decrease in the second E2-induced score relative to the first E2-induced score is predictive of an individual who is likely to respond to treatment with an endocrine therapy.

### Claim 115 (depends on 114)

The method of claim 114, wherein the second E2-induced score is decreased relative to the first E2-induced score, and the method further comprises administering an additional dose of the endocrine therapy to the individual.

### Claim 116 (depends on 114)

The method of claim 114, wherein the first E2-induced score is:
(a) an E2-induced score determined from a sample from the individual obtained prior to administration of a first dose of an endocrine therapy;
(b) an E2-induced score determined from a sample from the individual at a previous time point, wherein the previous time point is following administration of a first dose of an endocrine therapy; or
(c) a pre-assigned E2-induced score.

### Claim 117 (depends on 114)

The method of claim 114, wherein the endocrine therapy comprises a selective estrogen receptor degrader, a selective estrogen receptor modulator, a selective estrogen receptor covalent antagonist, a selective human estrogen receptor agonist, an aromatase inhibitor, or a combination of two or more thereof.

### Claim 118 (depends on 114)

The method of claim 114, wherein the endocrine therapy comprises letrozole, anastrozole, exemestane, testolactone, hydroxytamoxifen, clomifene, toremifene, raloxifene, anordrin, bazedoxifene, broparestrol, cyclofenil, lasofoxifene, ormeloxifene, acolbifene, elacestrant, brilanestrant, clomifenoxide, droloxifene, etacstil, ospemifene, G1T48, AZ9496, GDC-0927, LX-039, fulvestrant, or GDC −9545, a pharmaceutically acceptable salt of one of the foregoing, or a combination of two or more of the foregoing.

### Claim 119 (depends on 114)

The method of claim 114, wherein the endocrine therapy comprises a compound having formula:
or a pharmaceutically acceptable salt thereof.
